

(19)



Eur päisch s Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 874 050 A2

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
28.10.1998 Bulletin 1998/44

(51) Int Cl.6: C12N 15/15, C07K 14/47,  
C12N 5/10, C07K 16/18,  
A61K 31/70, C12Q 1/68,  
G01N 33/68, A61K 48/00

(21) Application number: 98300575.2

(22) Date of filing: 27.01.1998

(84) Designated Contracting States:  
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC  
NL PT SE  
Designated Extension States:  
AL LT LV MK RO SI

(30) Priority: 24.04.1997 US 845496

(71) Applicants:

- SMITHKLINE BEECHAM CORPORATION  
Philadelphia Pennsylvania 19103 (US)
- SMITHKLINE BEECHAM PLC  
Brentford, Middlesex TW8 9EP (GB)
- HUMAN GENOME SCIENCES, INC.  
Rockville, MD 20850-3338 (US)

(72) Inventors:

- Jonak, Zdenka L.  
King of Prussia, Pennsylvania 19406 (US)
- Trulli, Stephen H.  
King of Prussia, Pennsylvania 19406 (US)
- Fronwald, James A.  
King of Prussia, Pennsylvania 19406 (US)
- Hastings, Gregg A.,  
Rockville, MD 20850 (US)
- Terrett, Jonathan A.,  
SmithKline Beecham Pharma,  
Harlow, Essex, CM19 5AW (GB)

(74) Representative: Crump, Julian Richard John et al  
1J Cleveland,  
40-43 Chancery Lane  
London WC2A 1JQ (GB)

### (54) Integrin ligand ITGL-TSP

(57) ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment

of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling, among others, and diagnostic assays for such conditions.

**Description****FIELD OF INVENTION**

5 This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to thrombospondin-metalloproteinase family, hereinafter referred to as ITGL-TSP. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides.

**10 BACKGROUND OF THE INVENTION**

ITGL-TSP is a novel thrombospondin (metalloproteinase)-like gene which could have multifunctional activity in normal and disease states. The homology to the thrombospondin type 1 (TSP-1) would "predict" that ITGL-TSP could have similar functions such as TSP-1. TSP-1 modulates aggregation of platelets, formation and lysis of fibrin, adhesion and migration of cells and progression of cells through the growth cycle. TSP-1 is implicated as a potential regulator of tumor growth and metastasis. Conflicting observations suggest that overexpression of TSP-1 causes "increased or suppressed" tumor growth. TSP-1 is a homotrimer with different functional domains, some of which serve as receptor recognizing regions. One of the important functions has been its ability to bind to integrins, such as αVβ3, αIIbβ3 and other unknown integrin receptors. Integrins are a large family of cell surface receptors that mediate cell to cell as well as cell to matrix adhesion. Structurally, integrins consist of a heterodimer of an α and β chain. Each subunit has a large N-terminal extracellular domain followed by a transmembrane domain and a short C-terminal cytoplasmic region. Some receptors share a common β chain while having different α chains. ITGL-TSP could be a such novel ligand which could play an important role in different diseases.

The role of ITGL-TSP as an integrin ligand is of great interest due to its potential function in angiogenesis. Numerous angiogenic-related disorders have been described and the role of TSP-1 has been claimed in cancer/cancer metastasis. Our own research indicates that ITGL-TSP is "expressed" in numerous tissues (e.g., ovary, aorta, heart, prostate, placenta, skeletal muscle ...). From our data we estimated that ITGL-TSP gene maps to human chromosome 21q21. This is a similar chromosomal location to amyloid precursor protein (APP), enterokinases (enzymes that activates trypsinogen by converting it to trypsin) and genes responsible for Alzheimer's disease. The homology of the ITGL-TSP to the hemorrhagic toxin/metalloproteases would assign to the ITGL-TSP proteolytic functions (proteolyze extracellular matrix or basement membrane proteins). In summary, the role of ITGL-TSP as a ligand to the integrin receptors with metalloprotease activity fits its assigned role in angiogenesis, Alzheimers disease and tissue remodeling. This indicates that the thrombospondin-metalloproteinase family has an established, proven history as therapeutic targets. Clearly there is a need for identification and characterization of further members of the thrombospondin-metalloproteinase family which can play a role in preventing, ameliorating or correcting dysfunctions or diseases, including, but not limited to, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling.

**40 SUMMARY OF THE INVENTION**

In one aspect, the invention relates to ITGL-TSP polypeptides and recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such ITGL-TSP polypeptides and polynucleotides. Such uses include the treatment of angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling, among others. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with ITGL-TSP imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate ITGL-TSP activity or levels.

**50 DESCRIPTION OF THE INVENTION****Definitions**

55 The following definitions are provided to facilitate understanding of certain terms used frequently herein.  
 "ITGL-TSP" refers, among others, generally to a polypeptide having the amino acid sequence set forth in SEQ ID NO:2 or an allelic variant thereof.  
 "ITGL-TSP activity or ITGL-TSP polypeptide activity" or "biological activity of the ITGL-TSP or ITGL-TSP polypeptide" refers to the metabolic or physiologic function of said ITGL-TSP including similar activities or improved activities

or these activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said ITGL-TSP.

"ITGL-TSP gene" refers to a polynucleotide having the nucleotide sequence set forth in SEQ ID NO:1 or allelic variants thereof and/or their complements.

5 "Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.

10 "Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

15 "Polynucleotide" generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is a mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications has been made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

20 "Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from posttranslational natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993 and Wold, F., Posttranslational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis: Posttranslational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62.

25 "Variant" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitution, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct

synthesis.

"Identity" is a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. "Identity *per se*" has an art-recognized meaning and can be calculated using published techniques. See, e.g.: (COMPUTATIONAL MOLECULAR BIOLOGY, Lesk, A.M., ed., Oxford University Press, New York, 1988; BIOCOMPUTING: INFORMATICS AND GENOME PROJECTS, Smith, D.W., ed., Academic Press, New York, 1993; COMPUTER ANALYSIS OF SEQUENCE DATA, PART I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY, von Heijne, G., Academic Press, 1987; and SEQUENCE ANALYSIS PRIMER, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H., and Lipton, D., *SIAM J Applied Math* (1988) 48:1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H., and Lipton, D., *SIAM J Applied Math* (1988) 48:1073. Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCS program package (Devereux, J., et al., *Nucleic Acids Research* (1984) 12(1):387), BLASTP, BLASTN, FASTA (Atschul, S.F. et al., *J Molec Biol* (1990) 215:403).

As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO: 1 is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO: 1. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95 % identical to a reference nucleotide sequence, up to 5 % of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5 % of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

Similarly, by a polypeptide having an amino acid sequence having at least, for example, 95 % "identity" to a reference amino acid sequence of SEQ ID NO:2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO: 2. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5 % of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

#### Polypeptides of the Invention

In one aspect, the present invention relates to ITGL-TSP polypeptides. The ITGL-TSP polypeptides include the polypeptide of SEQ ID NO:2; as well as polypeptides comprising the amino acid sequence of SEQ ID NO: 2; and polypeptides comprising the amino acid sequence which have at least 80% identity to that of SEQ ID NO:2 over its entire length, and still more preferably at least 90% identity, and even still more preferably at least 95 % identity to SEQ ID NO: 2. Furthermore, those with at least 97-99% are highly preferred. Also included within ITGL-TSP polypeptides are polypeptides having the amino acid sequence which have at least 80% identity to the polypeptide having the amino acid sequence of SEQ ID NO:2 over its entire length, and still more preferably at least 90% identity, and still more preferably at least 95 % identity to SEQ ID NO:2. Furthermore, those with at least 97-99% are highly preferred. Preferably ITGL-TSP polypeptide exhibit at least one biological activity of ITGL-TSP.

The ITGL-TSP polypeptides may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

Fragments of the ITGL-TSP polypeptides are also included in the invention. A fragment is a polypeptide having an amino acid sequence that entirely is the same as part, but not all, of the amino acid sequence of the aforementioned ITGL-TSP polypeptides. As with ITGL-TSP polypeptides, fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 2140, 41-60, 61-80, 81-100, and 101 to the end of the ITGL-TSP polypeptide. In this context "about" includes

the particularly recited ranges larger or smaller by several, 5, 4, 3, 2 or 1 amino acid at either extreme or at both extremes.

Preferred fragments include, for example, truncation polypeptides having the amino acid sequence of ITGL-TSP polypeptides, except for deletion of a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus or deletion of two continuous series of residues, one including the amino terminus and one including the carboxyl terminus. Also preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Other preferred fragments are biologically active fragments. Biologically active fragments are those that mediate ITGL-TSP activity, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those that are antigenic or immunogenic in an animal, especially in a human.

Preferably, all of these polypeptide fragments retain the biological activity of the ITGL-TSP, including antigenic activity. Variants of the defined sequence and fragments also form part of the present invention. Preferred variants are those that vary from the referents by conservative amino acid substitutions -- i.e., those that substitute a residue with another of like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination.

The ITGL-TSP polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

#### 25 Polynucleotides of the Invention

Another aspect of the invention relates to ITGL-TSP polynucleotides. ITGL-TSP polynucleotides include isolated polynucleotides which encode the ITGL-TSP polypeptides and fragments, and polynucleotides closely related thereto. More specifically, ITGL-TSP polynucleotide of the invention include a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO: 1 encoding a ITGL-TSP polypeptide of SEQ ID NO: 2, and polynucleotide having the particular sequence of SEQ ID NO:1. ITGL-TSP polynucleotides further include a polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the ITGL-TSP polypeptide of SEQ ID NO:2 over its entire length, and a polynucleotide that is at least 80% identical to that having SEQ ID NO:1 over its entire length. In this regard, polynucleotides at least 90% identical are particularly preferred, and those with at least 95 % are especially preferred. Furthermore, those with at least 97% are highly preferred and those with at least 98-99% are most highly preferred, with at least 99% being the most preferred. Also included under ITGL-TSP polynucleotides are a nucleotide sequence which has sufficient identity to a nucleotide sequence contained in SEQ ID NO:1 to hybridize under conditions useable for amplification or for use as a probe or marker. The invention also provides polynucleotides which are complementary to such ITGL-TSP polynucleotides.

The ITGL-TSP of the invention is structurally related to other proteins of the thrombospondin-metalloproteinase family, as shown by the results of sequencing the cDNA encoding human ITGL-TSP. The cDNA sequence contains an open reading frame encoding a polypeptide of 967 amino acids. The amino acid sequence of Table 1 (SEQ ID NO:2) has about 100% identity in 63 amino acid residues and 95% identity in 721 amino acid residues (using Bestfit GCG) with mouse ADAM (A cellular disintegrin and metalloproteinase) (K. Kuno et al., JBC 272: 556-562, 1997). The sequence also has some homology to the human thrombospondin-1 (S. C. Hsu et al., Cancer Research 56: 5684-5691, 1996). The nucleotide sequence of Table 1 (SEQ ID NO:1) has about 82% identity (over the coding region) and 79% identity (over the entire sequence) (using Bestfit, GCG ) in 2370 (coding) and 3129 (entire sequence) nucleotide residues with ADAM mouse gene (K. Kuno et al., JBC 272:556-562, 1997).

50

55

Table I<sup>a</sup>

5	CCCA CG CGT CCG CCCA CG CGT CCGG CGG CT CCGAG CCAGGG CT ATT GCAAAG CCAGGGT	60
10	G CG CT A CCGG AC GG AG AGGG AGAG CCCT GAG CAG AGT GAG CAACAT CG CAG CCAAGG CG GAGG CCGAAGA gGGG CG CCAGG CACCAAT CT CCG CGTT G CCT CAG CCCCGGAGG CGCCCC	120
15	Ag Ag CG CTT CTT GT CCCAg CAGAg CCACT CTG CCT GCG CCTG CCT CT CAGT gT cT CCAAC TTTG CT CT GAGA AAA ACTT CUCGCG LG CCGG CAGAA cT G CAG CG CcT CcT CTT AGT GA U CCGGAG CTT CGG CT STACCCGcT G T G C CTT CCAACGAATAAT AGAAAT TGT	180
20	TAA TTT AA CAAT CCAGAG CAGG LCAA CG AGG CTT GcT CT CCCGACCGA ACT AAAG CT CCCT CG CT CCGT GCG CT GcT ACGAG CGGT GT CT CCT GGGG CT CCAAT G CAG CGAG CT GTG	240
25	M Q R A V CCCGAGGGTT CGGAAGG CG CAAG CT GGG CAG CG ACAT GGGG AAGC CGGAG CGGG CT CGG P E G F G R R K L G S D M G N A E R A P GGGT CT CGGAG CT TT GGG CCGT ACCCACG CT GCT GCT CGCCG CGG CG CT ACT GGC	300
30	G S R S E G P V P T L L L A A A L L A GTGT CGGACG CACT CGGG CGCCCT CGAGGAGGACGAGGAG CT AGT GGT GCGGAG CTG V S D A L G R P S E E D E E L V V P E L GAG CG CG CCCC CGGG ACACGGG ACCac qgcctcc GCCT GACG CCTT GACCAG CAG CTG	360
35	E R A P G H G T T R L R L H A F D Q Q L GAT CTGGAG CT GCGG CCGACAGGAG CTTT GCGCCGG CTT CACG CT CCAG PACGTG	420
40	D L E L R P D S S F L A P G F T L Q N V	480

35

40

45

50

55

## EP 0 874 050 A2

	GGGCGCAAATCCGGGTCCGAGACGCCGCTTCCGGAAACCGACCTGGGGCACTGCTCTAC	840
5	G R K S G S E T P L F E T D L A H C F Y	
	TCCGGCACCGTGAAATGGCGATCCCAGCTCGCTGCCGCCTCAGCCTCTGGAGGGCGTG	900
	S C T V N G D P S S A A A L S L C E G V	
	CGCGGCCGCCCCCTACCTGCTGGGGGAGGGCGTATTTCATCCAGCCGCTGCCCGCCAGC	960
10	R G A F Y L L G E A Y F I Q P L P A A S	
	GAGCGCCTCGCCACCGCCGCCAGGGAGAAGCCGCCGGCACCACTACAGTTCACACTC	1020
	E R L A T A A P G E K P P A P L Q F R L	
	CTGCCGGCGGAATCGGCAGGGCGACGTAGGCGGACCGTGCAGGGCTGGGCGACGGAGCC	1080
15	L R R N R Q G D V G G T C G V V D D E P	
	CAGCGACTGGAAAGCGGAGACCGAAGACGAGGACGAAGGGACTGAGGGCGAGGACGAA	1140
	R P T G K A E T E D E D E G T E G E D E	
	GGGCCTCAGTGGTCCCGCAGGACCCGGCACTGCAAGGGCTAGGACAGCCACAGGAAC	1200
20	G P Q W S P Q D P A L Q G V G Q P T G T	
	GGAAGCATAAAGAAAGCGATTTGTGTCAGTCACCGTATGTGGAAACCATGCTTG	1260
	G S I R K K R F V S S H R Y V E T M L V	
	GCAGACCAGTCgtggcagaattccaCGGCAGTGGTCTAAAGCATTACCTTCTCACGTTG	1320
25	A D Q S M A E F H G S G L K H Y L L T L	
	TTTCGGTGGCAGCCAGATTGTCAAACACCCAGATTGTAATTCTAGTAGCTGGTG	1380
	F S V A A R L Y K H P S I R N S V S L V	
	GTGGTGAAGATCTTGGTCAACCGATGAACAGAAGGGCGGAAGTGTGACCTCCATGCT	1440
30	V V K I L V I H D E Q K G P E V T S N A	
	GCCCTCACTCTGCGAACCTTTGCAACTGGCAGAAGCAGCACAAACCCACCCAGTGACCGG	1500
	A L T L R N F C N W Q K Q H N P P S D R	
	GATGCAGAGCACTATGACACAGCAATTCTTTCACCAGACAGGACTTGTGTGGGTCCCAG	1560
35	D A E H Y D T A I L F T R Q D L C G S Q	
	ACATGTGATACTCTGGATGGCTGATGTTGAACTGTGTGATCCGAGCAGAAGCTGC	1620
	T C D T L G M A D V G T V C D P S R S C	
	TGGTCTACAAGATGATGGTTACAAGCTGCCTCACACAGCCCATGAATTAGGCCAG	1680
40	S V T E D D G L Q A A F T T A H S L C H	
	GTGTTTACATGCGCATGATGATGCAAAGCAGTGTGCCAGCCTTAATGGTGTGAACAG	1740
	V F N M P H D D A K Q C A S L N G V N Q	
	GATTCCACATGATGGCGTCAATGCTTCCACCTGGACCACAGCCAGCCTGGCTCCT	1800
45	D S H M M A S M L S N L D H S Q P W S P	
	TGCAGTGCCTACATGATTACATCATCTGGATAATGGTCATGGGAATGTTGATGGAC	1860
	C S A Y M I T S F L D N G H G E C L M D	
	AAGCTCAGAATCCCATACAGCTCCAGGCGATCTCCCTGGACCTCGTACGATGCCAAC	1920
50	K P Q N P I Q L P G D L P G T S Y D A N	
	GGTAGTGCAGTTACATTTGGGAGGACTCCAAACACTGCCCTGATGAGGCCAGACA	1980
	R Q C Q F T F G E D S K H C P D A A S T	
	TgTAGCACCTCTGGTGTACCGGCACCTCTGGTGGGTGCTGGTGTGTAAACCAACAC	2040
55	C S T L W C T G T S G G V L V C Q T K H	
	TTCCCGTGGCGGATGGCAACAGTGTGGAGAAGGAAATGGTGTATCAACGGCPAGTGT	2100

## EP 0 874 050 A2

	F P W A D G T S C G E G K W C I N G K C	
5	GTGAACAAAACCGACAGAAAGcATTTGATACGCCCTTCATGGAAGCTGGGGAAATGTGG	2160
	V N K T D R K H F D T F F H G S W G M N	
	GGGCTTGGGAGACTGTT CGAGAACGTGCGGTGGAGGAGTCCAGTACACGGATGAGGGAA	2220
10	G P W G D C S R T C G G G V Q Y T M R E	
	TGTGACACCCAGTCCCAAAGAATGGAGGGAAAGTACTGTGAAGGCAAACGAGTGCCTAC	2280
	C D N P V P K N G G K Y C E G K R V R Y	
	AGATCCTGTAACCTTGAGGACTGTCCAGACAAATATGGAAAAACCTTAGAGAGGAACAA	2340
15	R S C N L E D C P D N N G K T F R E E D	
	TGTGAAAGCACACAACGGAGTTTCAAAAGCTT CCTTGGGAGTGGCCTGCGGTGGAATGG	2400
	C S A H N E F S K A S F G S G P A V E N	
	ATTCCGAGTACGCTGGCGTCTCACCAAAGGACAGGTGCAAGCTCATCTGCCAACGCCAA	2460
20	I P K Y A G V S P K D R C K L I C Q A K	
	GGCATGGCTACTTCTTCTGTTGAGCCCAGGTTGTACATCGTACTCCATGTAGCCC	2520
	G I G Y F F V L Q P K V V D G T P C S P	
	GATTCCACCTCTGTCTGTGCAAGGACAGTGTAAAAGCTGGTGTGATCGCATCAT	2580
25	D S T S V C V Q G Q C V K A G C D R I I	
	GACTCCAAAAAGAAGTTGATAAAATGTGGTGTGTTGCGGGGGAAATGGATCTACTTGTAAA	2640
	D S K K K F D K C G V C G G N G S T C K	
	AAAATATCAGGATCAGTTACTAGTGCAAAACCTGGATATCATGATATCATCACAATTCCA	2700
30	K I S G S V T S A K P G Y H D I I T I P	
	ACTGGAGCCACCAACATCGAAGTGAACAGCGGAACCAGAGGGGATCCAGGAACAATGGC	2760
	T G A T N I E V K Q R N Q R G S R N N G	
	AGCTTTCTTGCCTCAAAGCTGCTGATGGCACATAATTCTTATGGTGAACACTTTC	2820
35	S F L A I K A A D G T Y I L N G D Y T L	
	TCCACCTTAGAGCAAGACATTATGTACAAAGGTGTTGTCAGGTTACAGCGGCTCCTCT	2880
	S T L E Q D I M Y K G V V L R Y S G S S	
	GCGGCATTGGAAAAGAATT CGCAGCTTAGCCCTCTCAAAGAGCCCTGACCATCCAGGTT	2940
40	A A L E R I R S F S P L K E P L T I Q V	
	CTTACTGTGGGCAATGCCCTTCCACCTAAATTAATACACCTACTTGTAAAGAAGAAG	3000
	L T V G N A L R P K I K Y T Y F V K K K	
	AAGGAATCTTCACTGCTATCCCCACTTTTCAAGCATGGGTCAATGAAGAGTGGGGCGAA	3060
45	K E S F N A I P T F S A W V I E E W G E	
	TGTTCTAAGTCATGTGAAATTGGGTTGGCAGAGAAGACTGGTAGAATGCCAGACATTAT	3120
	C S K S C E L G W Q R R L V E C R D I N	
	GGACAGGCTGCTTCCAGTGTGCAAAGGAAGTGAAGGCCAGCACCAGACCTGTGCA	3180
50	G Q P A S E C A K E V K P A S T R P C A	
	GACCATCCCTGCCCTCAGCTGGAGCTGGGGAGTGGTCAICATGTTCTAAGACCTGTGG	3240
	D H P C P Q W Q L G E W S S C S K T C G	
	AAGGGTTACAAAAAAAAGAAGCTTGAAGTGTCTGTCCCATGATGGAGGGGTGTTATCTCAT	3300
55	K G Y K K R S L K C L S H D G G V L S H	
	GAGAGCTGTGATCTTTAAAGAAACCTAAACATTTCAAGACTTTGACAATGGCAGAA	3360
	E S C D P L K K P K H F I D F C T M A E	

5	TG CAGTT AAGTGGTT AAGT GGTGTT AG CTTGAGGG CAAGG CAAAGTGAGGAAGGGCTG C S *	3420
10	GT GCAGGGAAAGCAAGAAGGCTGGAGGGATCCAGCGTATCTTGCAGTAAACAGTCAGGT GT AT CAGTAAGGTGGGATTATGGGGTAGATAGAAAAGGAGTTGAATCATCAGAGTAAC TG CCAGTTGCAAATTGATAGGATAGTTAGTGAGGATTATTAACCTCTGAGCAGTGTAT AGCATATAAAGCCCCGGGCATTATTATTATTCTTTGTTACATCTATTACAAGTT TAGAAAAAAACAAAGCAATTGTCAAAAAAAAGTTAGAACTATTACAACCCCTGTTCTGGT ACTTATCAAATACTTAGTATCATGGGGGTTGGGAATGAAAAGTAGGAGGAAAGTGAGAT TTTACTAAGACCTGTTTACTTACCTCACTAAACAATGGGGGAGAAAGGAGTACAAAT AGGATCTTTGACCAGCACTGTTATGGGCTGCTATGGTTCAGAGAATGTTTATACATT ATTCTACCGAGGATTAAAACITCCAGATGTTCCAACATGGAGAGGAAAGGCTCAGGC AACGTGGAAATAACGCAATGGCTTCCCCCTTCCCTTTGGGACCCACTCCAG	3480 3540 3600 3660 3720 3780 3840 3900 3960 4014
15		
20		

<sup>a</sup> Nucleotide and deduced amino acid sequence from a human ITGL-TSP. SEQ ID NOS: 1 and 2, respectively.

25 One polynucleotide of the present invention encoding ITGL-TSP may be obtained using standard cloning and screening, from a cDNA library derived from mRNA in cells of human adipocytes using the expressed sequence tag (EST) analysis (Adams, M.D., et al. *Science* (1991) 252:1651-1656; Adams, M.D. et al., *Nature*, (1992) 355:632-634; Adams, M.D., et al., *Nature* (1995) 377 Supp:3-174). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

30 The nucleotide sequence encoding the ITGL-TSP polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in Table 1 (SEQ ID NO: 1), or it may be a sequence, which as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2.

35 When the polynucleotides of the invention are used for the recombinant production of the ITGL-TSP polypeptide, the polynucleotide may include the coding sequence for the mature polypeptide or a fragment thereof, by itself; the coding sequence for the mature polypeptide or fragment in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein Sequence, or other fusion peptide portions. For example, a marker sequence which facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz et al., *Proc Natl Acad Sci USA* (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

40 Further preferred embodiments are polynucleotides encoding ITGL-TSP variants comprise the amino acid sequence ITGL-TSP polypeptide of Table 1 (SEQ ID NO:2) in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acid residues are substituted, deleted or added, in any combination.

45 The present invention further relates to polynucleotides that hybridize to the herein above-described sequences. In this regard, the present invention especially relates to polynucleotides which hybridize under stringent conditions to the herein above-described polynucleotides. As herein used, the term "stringent conditions" means hybridization will occur only if there is at least 95 % and preferably at least 97 % identity between the sequences.

50 Polynucleotides of the invention, which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO:1 or a fragment thereof, may be used as hybridization probes for cDNA and genomic DNA, to isolate full-length cDNAs and genomic clones encoding the ITGL-TSP polypeptide and to isolate cDNA and genomic clones of other genes that have a high sequence similarity to the ITGL-TSP gene. Such hybridization techniques are known to those of skill in the art. Typically these nucleotide sequences are 80% identical, preferably 90% identical, more preferably 95% identical to that of the referent. The probes generally will comprise at least 15 nucleotides. Preferably, such probes will have at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will range between 30 and 50 nucleotides.

55 In one embodiment, to obtain a polynucleotide encoding ITGL-TSP polypeptide comprises the steps of screening an appropriate library under stringent hybridization conditions with a labeled probe having the SEQ ID NO: 1 or a

fragment thereof; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to those of skill in the art. Stringent hybridization conditions are as defined above or alternatively conditions under overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

The polynucleotides and polypeptides of the present invention may be employed as research reagents and materials for discovery of treatments and diagnostics to animal and human disease.

#### 10 Vectors, Host Cells, Expression

The present invention also relates to vectors which comprise a polynucleotide or polynucleotides of the present invention, and host cells which are genetically engineered with vectors of the invention and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al., *BASIC METHODS IN MOLECULAR BIOLOGY* (1986) and Sambrook et al., *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. 1989 such as calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila S2* and *Spodoptera Sf9* cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used. Such systems include, among others, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., *MOLECULAR CLONING, A LABORATORY MANUAL* (*supra*).

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the desired polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If the ITGL-TSP polypeptide is to be expressed for use in screening assays, generally, it is preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the ITGL-TSP polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide; if produced intracellularly, the cells must first be lysed before the polypeptide is recovered. ITGL-TSP polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and/or purification.

#### 50 Diagnostic Assays

This invention also relates to the use of ITGL-TSP polynucleotides for use as diagnostic reagents. Detection of a mutated form of the ITGL-TSP gene associated with a dysfunction will provide a diagnostic tool that can add to or define a diagnosis of a disease or susceptibility to a disease which results from under-expression, overexpression or altered expression of ITGL-TSP. Individuals carrying mutations in the ITGL-TSP gene may be detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy

or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled ITGL-TSP nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures.

5 DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g., Myers et al., *Science* (1985) 230:1242. Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method. See Cotton et al., *Proc Natl Acad Sci USA* (1985) 85: 4397-4401.

10 In another embodiment, an array of oligonucleotides probes comprising ITGL-TSP nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability. (See for example: M.Chee et al., *Science*, Vol 274, pp 610-613 (1996)).

15 The diagnostic assays offer a process for diagnosing or determining a susceptibility to, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling through detection of mutation in the ITGL-TSP gene by the methods described.

20 In addition, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling can be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of the ITGL-TSP polypeptide or ITGL-TSP mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques 25 that can be used to determine levels of a protein, such as an ITGL-TSP polypeptide, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

#### Chromosome Assays

30 The nucleotide sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, *Mendelian Inheritance in Man* (available on line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

35 The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease. From our data we estimated that ITGL-TSP gene maps between STS markers D21S1435 and D21S1442 which translates as 21q21. This is a similar chromosomal location to amyloid precursor protein (APP), and thus, we have mapped APP in relation to ITGL-TSP. They are approximately 40 3 million bases apart which is not a massive distance in human genomics. The chromosomal location includes important genes such as enterokinases (enzymes that activate trypsinogen by converting it to trypsin) and genes responsible for Alzheimer's disease.

45 We mapped the ITGL-TSP to the 21q21 chromosomal location. The oligo sequences that were used for Radiation Hybrid mapping are as follows:

50 F 5' actgtgtgtatccgag 3' (SEQ ID NO: 3)

55 R 5' gttggaaaggattgacg 3' (SEQ ID NO: 4)

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the cDNA. Computer analysis of the cDNA is used to rapidly select primers that do not span more than one exon in the

genomic DNA, thus complicating the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the primer will yield an amplified fragment.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular DNA to a particular chromosome. Using the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner. Other mapping strategies that can similarly be used to map to its chromosome include Radiation Hybrid mapping, prescreening with labeled flow-sorted chromosomes and preselection by hybridization to construct chromosome specific cDNA libraries. Radiation Hybrid (RH) mapping relies upon fragmentation of human chromosomes with X-rays, and retention of these random fragments in Hamster A23 host cells. The DNAs for RH mapping are supplied by Research Genetics (USA). Oligo pairs are designed from EST sequences that will amplify products of between 80bp and 300bp. The PCRs are performed on 93 human/hamster hybrid DNAs and the results compared with a framework map (<http://www-genome.wi.mit.edu/cgi-bin/contig/rhMapper.pl>, Gyapay, G et al 1996) Human Molecular Genetics 5 : 339-346. RH mapping provides greater precision than FISH and indicates clusters of genes as well as disease locus/gene correlations.

#### 15      Antibodies

The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them can also be used as immunogens to produce antibodies immunospecific for the ITGL-TSP polypeptides. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against the ITGL-TSP polypeptides can be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole et al., MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.

Antibodies against ITGL-TSP polypeptides may also be employed to angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling, among others.

#### Vaccines

Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with ITGL-TSP polypeptide, or a fragment thereof, adequate to produce antibody and/or T cell immune response to protect said animal from, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling, among others. Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering ITGL-TSP polypeptide via a vector directing expression of ITGL-TSP polynucleotide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases.

Further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a ITGL-TSP polypeptide wherein the composition comprises a ITGL-TSP polypeptide or ITGL-TSP gene. The vaccine formulation may further comprise a suitable carrier. Since ITGL-TSP polypeptide may be broken down in the stomach, it is preferably administered parenterally (including subcutaneous, intramuscular, intravenous, intradermal etc. injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in-

water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

#### Screening Assays

5 The ITGL-TSP polypeptide of the present invention may be employed in a screening process for compounds which activate (agonists) or inhibit activation of (antagonists, or otherwise called inhibitors) the ITGL-TSP polypeptide of the present invention. Thus, polypeptides of the invention may also be used to assess identify agonist or antagonists from, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These agonists or antagonists may be natural substrates, ligands, receptors, etc., as the case may be, of the polypeptide of the present invention; or may be structural or functional mimetics of the polypeptide of the present invention. See Coligan *et al.*, *Current Protocols in Immunology* 1(2):Chapter 5 (1991).

10 ITGL-TSP polypeptides are responsible for many biological functions, including many pathologies. Accordingly, it is desirous to find compounds and drugs which stimulate ITGL-TSP polypeptide on the one hand and which can inhibit the function of ITGL-TSP polypeptide on the other hand. In general, agonists are employed for therapeutic and prophylactic purposes for such conditions as, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling. Antagonists may be employed for a variety of therapeutic and prophylactic purposes for such conditions, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling.

15 20 25 In general, such screening procedures may involve using appropriate cells which express the ITGL-TSP polypeptide or respond to ITGL-TSP polypeptide of the present invention. Such cells include cells from mammals, yeast, *Drosophila* or *E. coli*. Cells which express the ITGL-TSP polypeptide (or cell membrane containing the expressed polypeptide) or respond to ITGL-TSP polypeptide are then contacted with a test compound to observe binding, or stimulation or inhibition or a functional response. The ability of the cells which were contacted with the candidate compounds is compared with the same cells which were not contacted for ITGL-TSP activity. The assays which will be routinely used are: Enzyme-linked immunosorbent sandwich assay (ELISA); receptor binding/inhibition assay; inhibition of cell adhesion/migration/proliferation assay; assays which utilize neutralizing mAbs against other integrin ligands/receptors; competition assays with integrin ligands/receptors.

30 35 The assays may simply test binding of a candidate compound wherein adherence to the cells bearing the ITGL-TSP polypeptide is detected by means of a label directly or indirectly associated with the candidate compound or in an assay involving competition with a labeled competitor. Further, these assays may test whether the candidate compound results in a signal generated by activation of the ITGL-TSP polypeptide, using detection systems appropriate to the cells bearing the ITGL-TSP polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Standard methods for conducting such screening assays are well understood in the art.

40 Examples of potential ITGL-TSP polypeptide antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligands, substrates, receptors, etc., as the case may be, of the ITGL-TSP polypeptide, e.g., a fragment of the ligands, substrates, receptors, or small molecules which bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

#### Prophylactic and Therapeutic Methods

45 This invention provides methods of treating an abnormal condition related to both an excess of and insufficient amounts of ITGL-TSP polypeptide activity.

If the activity of ITGL-TSP polypeptide is in excess, several approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as hereinabove described along with a pharmaceutically acceptable carrier in an amount effective to inhibit activation by blocking binding of ligands to the ITGL-TSP polypeptide, or by inhibiting a second signal, and thereby alleviating the abnormal condition.

In another approach, soluble forms of ITGL-TSP polypeptides still capable of binding the ligand in competition with endogenous ITGL-TSP polypeptide may be administered. Typical embodiments of such competitors comprise fragments of the ITGL-TSP polypeptide.

55 In still another approach, expression of the gene encoding endogenous ITGL-TSP polypeptide can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or separately administered. See, for example, O'Connor, *J Neurochem* (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Alternatively, oligonucleotides which form triple helices with the gene can be supplied. See, for example, Lee *et al.*, *Nucleic Acids Res* (1979) 6:3073;

Cooney *et al.*, *Science* (1988) 241:456; Dervan *et al.*, *Science* (1991) 251:1360. These oligomers can be administered *per se* or the relevant oligomers can be expressed *in vivo*.

For treating abnormal conditions related to an under-expression of ITGL-TSP and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates ITGL-TSP polypeptid , i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of ITGL-TSP by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo*. For overview of gene therapy, see Chapter 20, *Gene Therapy and other Molecular Genetic based Therapeutic Approaches*, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996).

#### 15 Formulation and Administration

Peptides, such as the soluble form of ITGL-TSP polypeptides, and agonists and antagonist peptides or small molecules, may be formulated in combination with a suitable pharmaceutical carrier. Such formulations comprise a therapeutically effective amount of the polypeptide or compound, and a pharmaceutically acceptable carrier or excipient. Such carriers include but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. Formulation should suit the mode of administration, and is well within the skill of the art. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

25 Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

Preferred forms of systemic administration of the pharmaceutical compositions include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if properly formulated in enteric or encapsulated formulations, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels and the like.

The dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 µg/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

40 Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide *ex vivo*, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

#### 45 Examples

The example below is carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The example illustrates, but does not limit the invention.

#### 50 Example 1

##### ITGL-TSP Cloning Strategy

###### Cloning history:

55 The Metalloprotease with TSR homology clone (METH-1) was first identified in a cDNA library prepared from human adipocytes obtained from an osteoclastoma. The clone was identified as a novel human protein possessing homology to the thrombospondin type 1 repeat, as well as to several hemorrhagic proteins. The initial identification of the METH-

1, cDNA clone was made using a previously described thrombospondin type 1 repeat sequence as a query sequence in the BLASTN and TBLASTN sequence alignment algorithms (Altschul, S.F., Gish, W., Miller, W., Myers, E.W., and Lipman, D. J. (1990) *J. Mol. Biol.* 215:403-410) against the Human Genome Sciences, Inc. EST database. A single EST clone was identified by this method as a potentially novel human hemorrhagic protein.

5       The cDNA clone initially identified in the BLAST analyses was thought to lack about 1.4 kb of 5' sequence, and, as a result, did not appear to be a full-length clone. However, the clone was useful as a probe to perform additional screens to obtain a full-length cDNA copy of the METH-1 gene. In this regard, METH-1-specific oligonucleotides were designed from sequence information obtained from the partial cDNA and were then used in conjunction with the Gene Trapper™ cDNA Positive Selection System kit (Life Technologies, Grand Island, NY) to screen a human pCMVSPORT  
10      kidney cDNA library for a full-length clone. Briefly, a biotinylated METH-1-specific oligonucleotide was hybridized to a complex population consisting of single-stranded copies of the  $10^6$  to  $10^7$  individual cDNA clones which make up the human pCMVSPORT kidney library. Hybrids consisting of the biotinylated METH-1-specific oligonucleotide hybridized to various single-stranded cDNA clones were captured by streptavidin-coated magnetic beads. A magnet was used  
15      to separate the magnetic beads from the solution which contained the entire single-stranded library. Following several washing steps, the single-stranded cDNA clone was primed with Klenow DNA polymerase using a second METH-1-specific oligonucleotide. Electromax DH10B™ electrocompetent *E. coli* cells (Life Technologies, Grand Island, NY) were transformed with the rescued cDNA clones and PCR was used to screen the resulting colonies for full-length cDNA clones of the METH-1 gene. The full-length cDNA copy of the METH-1 ORF was subsequently cloned into the bacterial and baculovirus expression vectors pQE-9 (Qiagen, Inc., Chatsworth, CA) and pA2GP, respectively, for the  
20      production and purification of METH-1 protein.

25

30

35

40

45

50

55

Annex to the description

SEQUENCE LISTING

5

(I) GENERAL INFORMATION

10

(i) APPLICANTS: SmithKline Beecham Corporation,  
SmithKline Beecham p.l.c. and  
Human Genome Sciences Inc

15

(ii) TITLE OF THE INVENTION: Novel Integrin Ligand ITGL-TSP

(iii) NUMBER OF SEQUENCES: 4

20

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: F J Cleveland & Company
- (B) STREET: 40/43 Chancery Lane
- (C) CITY: London
- (D) COUNTY:
- (E) COUNTRY: United Kingdom
- (F) POST CODE: WC2A 1JQ

25

(v) COMPUTER READABLE FORM:

30

- (A) MEDIUM TYPE: Diskette
- (B) COMPUTER IBM Compatible
- (C) OPERATING SYSTEM: DOS
- (D) SOFTWARE: FastSEQ for Windows Version 2.0

35

(vi) CURRENT APPLICATION DATA:

40

- (A) APPLICATION NUMBER:
- (B) FILING DATE: 24-APR-1997
- (C) CLASSIFICATION:

45

(vii) PRIOR APPLICATION DATA:

50

- (A) APPLICATION NUMBER:
- (B) FILING DATE:

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: CRUMP, Julian Richard John
- (B) GENERAL AUTHORISATION NUMBER 37127 and 37129
- (C) REFERENCE/DOCKET NUMBER GH-70000

55

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: +44 171 405 5875  
 (B) TELEFAX: +44 171 831 0749  
 (C) TELEX:

5

## (2) INFORMATION FOR SEQ ID NO: 1:

10

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4014 base pairs  
 (B) TYPE: nucleic acid  
 15 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

20

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

25	CCCACGGCGTC CGCCCCACGCG TCCGGCGGCT CCGAGCCAGG GGCTATTGCA AAGCCAGGGT GCGCTACCGG ACGGAGAGGG GAGAGGCCCTG AGCAGAGTGA GCAACATCGC AGCCAAGGGCG GAGGCCGAAG AGGGGCGCCA GGCACCAATC TCCCGTTGC CTCAAGCCCG GAGGCCGCCCC AGAGCGCTTC TTGTCCCAGC AGAGCCACTC TGCCCTGCGCC TGCCTCTCAG TGTCTCCAAC TTTGCCTGG AAGAAAAACT TCCCGCGCGC CGGCAGAACT GCAGCGCTC CTCTTAGTGA 30 CTCCGGGAGC TTGGCTGTGTA GCGGGCTCTG CGCGCCCTC CAACGAATAA TAGAAATTGT TAATTTAAC AATCCAGAGC AGGCCAACGA GGCTTGCTC TCCCGACCCG AACTAAAGCT CCCTCGCTCC GTGCGCTGCT ACGAGCGGTG TCTCTGGGG CTCCAATGCA GCGAGCTGTG CCCCAGGGGT TCGGAAGGGCG CAAGCTGGGC AGCGACATGG GGAACCGGGA GCGGGCTCCG 35 GGGCTCTCGGA GCTTTGGGCC CGTACCCACG CTGCTGCTGC TCGCCCGGC GCTACTGGCC GTGTGGACG CACTCGGGCG CCCCTCCGAG GAGGACGAGG AGCTAGTGGT GCCGGAGCTG GAGGCCCGG CGGGACACCG GACCAACGCG CTCCGCTGAC CGCCCTTGA CCAGCAGCTG CATCTGGACG TGGCTCCCGA CAGCAGCTTT TTGGCGCCCG CCTTCAAGCT CCAGAACGTG 40 GGGCGCAAAT CGGGGTCCGA CACCCCGCTT CGGGAAACCG ACCTGGCGCA CTGCTTCTAC TCUGGCACCG TGAATGGCGA TCCCAGCTCG GCTGCGGCCCTCAGCCTCTG CGAGGGCGTG CGCGGCCCT TCTACCTGCT GGGGGAGCG TATTTCATCC AGCCGCTGCC CGCCGCCAGC GAGGCCCTCG CCACCGCGC CCCAGGGAG AAGCCGCGCG CACCACTACA GTTCCACCTC 45 CTGGGGCGGA ATCGGCAGGG CGACGTAGGC GGCACTGCG GGGTCGTGGA CGACGGAGCC CGGCCGACTG GGAAAGCGGA GACCGAAGAC GAGGACGAAG GGACTGAGGG CGAGGACGAA GGCCCTCAGT GGTGGCGCA GGACCCGGCA CTGCAAGGCG TAGGACAGCC CACAGGAAC GGAAGCTAA GAAAGAACCG ATTTGTGTC AGTCACCGCT ATGTGGAAAC CATGCTTGTG 50 GCAACCGACT CGATGGCAGA ATTCCACGGC AGTGGCTAA AGCATTACCT TCTCAAGCTG TTTCCGGTGG CAGCCAGATT GTACAAACAC CCCAGCACTC GTAAATTCACT TAGCCTGCTG CTGCTGAAGA TCTTGGTCT CCACGATGAA CAGAAGGGGC CGCAAGTGAC CTCCAATGCT 55 GCCCTCACTC TGCGGAACCTT TTGCAACTGG CAGAAGCAGC ACAACCCACC CAGTGACCGG GATGCAAGAC ACTATGACAC AGCAATTCTT TTCAACGACAGGACTTGTG TGGGTCCAG	60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560
----	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

	ACATGTGATA CT CTTGGGAT GGCTGATGTT GGAACIGTGT GTGATCCGAG CAGAAGCTGC	1620
5	TCCGT CATAG AAGATGATGG TTTACAAGCT GCCTT CACCA CAGCCCATGA ATTAGGCCAC	1680
	GTGTTAACATGCCACATGA TGATGCAAAG CAGTGTGCCA GCCTTAATGG TGTGAACCAG	1740
	GATTCCCACA TGATGGCGTC AATGCTTCC AACCTGGACC ACAGCCAGCC TTGGCTCCT	1800
	TGCACTGCCT ACATGATTAC ATCATTTCTG GATAATGGTC ATGGGGAAATG TTTGATGGAC	1860
10	AAGCCT CAGA ATCCCATACA GCTCCCAGGC GATCTCCCTG GCACCTCGTA CGATGCCAAC	1920
	CGGCAGTGCCT AGTTTACATT TGGGGAGGAC TCCAAACACT GCCCTGATGC AGCCAGCAC	1980
	TGTAGCACCT TGTGGTGTAC CGGCACCTCT GGTGGGGTGC TGGTGTGTCA AACCAAACAC	2040
	TTCCCCTGGG CGGATGGCAC CAGCTGTGCA CAAGGGAAAT GGTGTATCAA CGGCAAGTGT	2100
15	GTGAAACAAAA CCCACAGAAA GCATTTGAT AGCCCTTTTC ATGGAAGCTG GGGATGTGG	2160
	GGGCTTGGG GAGACTGTTC GAGAACGTGC GGTGGAGGAG TCCAGTACAC GATGAGGGAA	2220
	TGTGACAACC CAGTCCAAA GAATGGAGGG AAGTACTGTG AAGGCAAACG AGTGCCTAC	2280
	AGATCCTGTA ACCTTGAGGA CTGTCAGAC AATAATGGAA AACCTTAG AGAGGAACAA	2340
20	TGTGAAGCAC ACAACGAGTT TCTAAAGCT TCTTTGGGAT GTGGCCTGC GGTGGAATGG	2400
	ATTCCCAAGT ACGCTGGGCT CT CACCAAAAG GACAGGTGCA AGCTCATCTG CCAAGCCAAA	2460
	GGCATTGGCT ACTTCTTGT TTTGCAGCCC AAGGTTGTAG ATGGTACTCC ATGTAGCCCA	2520
	GATTCCACCT CTGTCTGTGT GCAAGGACAG TGTGTAAAAG CTGGTTGTGA TCGCATCATA	2580
25	GACTCCAAA AGAAGTTTGA TAAATGTGGT GTTTGCGGGG GAAATGGATC TACTTGTAAA	2640
	AAAATATCAG GATCAGTTAC TAGTGCAGGAA CCTGGATATC ATGATATCAT CACAATTCCA	2700
	ACTGGAGCCA CCAACATCGA AGTGAACACG CGGAACCCAGA GGGGATCCAG GAACAATGGC	2760
	AGCTTTCTTG CCATCAAAGC TGCTGATGGC ACATATATTCTTAATGGTGA CTACACTTG	2820
	TCCACCTTAG AGCAAGACAT TATGTACAAA GGTGTTGTCT TGAGGTACAG CGGCTCCTCT	2880
30	GCGGCATTGG AAAGAATT CG CAGCTTAGC CCTCTCAAAG AGCCCTGAC CATCCAGGTT	2940
	CTTACTGTGG GCAATGCCCT TCGACCTAAA ATTAAATACA CCTACTTGT AAAGAAGAAG	3000
	AAGGAATCTT TCAATGCTAT CCCCCACTTT TCAGCATGGG TCATTGAAGA GTGGGGCGAA	3060
	TGTTCTAAGT CATGTGAATT GGGTTGGCAG AGAAGACTGG TAGAATGCCG AGACATTAAT	3120
35	GGACAGCTG CTTCCGAGTG TGCAAAGGAA GTGAAGCCAG CCAGCACCAG ACCTTGTGCA	3180
	GACCATCCCT GCCCCCAGTG GCAGCTGGGG GAGTGGTCA CATGTTCTAA GACCTGTGGG	3240
	GGGGTTACA AAAAAGAAG CTTGAAGTCT CTGTCCCAGT ATGGAGGGGT GTTATCTCAT	3300
40	GAKAGGTTCT ATCTTTAAAG GAAACCTAAA CATTTCATAG ATTTTGCAC ATGGCCAGAA	3360
	TGCAGTTAAG TGCTTTAAGT GGTGTTAGCT TTGAGGGCAA GGCAAAGTGA GGAAGGGCTG	3420
	GTGCAGGGAA AGCAAGAAGG CTGGAGGGAT CCAGCGTATC TTGCCAGTAA CCAGTGAGGT	3480
	GTATCAGTAA GGTGGGATTA TGGGGTAGA TAGAAAAGGA GTTGAATCAT CAGAGTAAAC	3540
45	TGCCAGTTGC AAATTTGATA GGATAGTTAG TGAGGATTAT TAACCTCTGA GCAGTGTAT	3600
	AGCATAATAA AGCCCCGGGC ATTATTATTA TTATTTCTTT TGTTACATCT ATTACAAGTT	3660
	TAGAAAAAAAC AAAGCAATTG TCAAAAAAAAG TTAGAACTAT TACAAACCCCT GTTCTGGT	3720
	ACTTATCAA TACTTAGTAT CATGGGGTT CGGAAATGAA AAGTAGGAGA AAAGTGAGAT	3780
50	TTTACTAAGA CCTGTTTAC TTTACCTCAC TAAACAAATGG GGGGAGAAAAG GAGTACAAAT	3840
	AGGATCTTTT GACCAGCACT GTTATGGGC TGCTATGGTT TCAGAGAATG TTTATACATT	3900
	ATTCTACCG AGGATTTAAA ACTTCCAGAT TGTTCCAACA TGGAGAGGAA AGGCTCAGGC	3960
	AACGTGGAAA TAACGCAATG GGCTTCCCCC TTCCCTTTT GGGACCCACT CCAG	4014

55

(2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 967 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

15	Met	Gln	Arg	Ala	Val	Pro	Glu	Gly	Phe	Gly	Arg	Arg	Lys	Leu	Gly	Ser
	1				5					10				15		
	Asp	Met	Gly	Asn	Ala	Glu	Arg	Ala	Pro	Gly	Ser	Arg	Ser	Phe	Gly	Pro
20						20				25				30		
25	Val	Pro	Thr	Leu	Leu	Leu	Leu	Ala	Ala	Ala	Leu	Leu	Ala	Val	Ser	Asp
						35				40			45			
	Ala	Leu	Gly	Arg	Pro	Ser	Glu	Glu	Asp	Glu	Glu	Leu	Val	Val	Pro	Glu
30						50				55			60			
35	Leu	Glu	Arg	Ala	Pro	Gly	His	Gly	Thr	Thr	Arg	Leu	Arg	Leu	His	Ala
						65			70			75			80	
	Phe	Asp	Gln	Gln	Leu	Asp	Leu	Glu	Leu	Arg	Pro	Asp	Ser	Ser	Phe	Leu
40						85				90			95			
45	Ala	Pro	Gly	Phe	Thr	Leu	Gln	Asn	Val	Gly	Arg	Lys	Ser	Gly	Ser	Glu
						100				105			110			
	Thr	Pro	Leu	Pro	Glu	Thr	Asp	Leu	Ala	His	Cys	Phe	Tyr	Ser	Gly	Thr
50						115				120			125			
55	Val	Asn	Gly	Asp	Pro	Ser	Ser	Ala	Ala	Ala	Leu	Ser	Leu	Cys	Glu	Gly
						130			135			140				
	Val	Arg	Gly	Ala	Phe	Tyr	Leu	Leu	Gly	Glu	Ala	Tyr	Phe	Ile	Gln	Pro
60						145			150			155			160	
65	Leu	Pro	Ala	Ala	Ser	Glu	Arg	Leu	Ala	Thr	Ala	Ala	Pro	Gly	Glu	Lys
						165				170			175			
	Pro	Pro	Ala	Pro	Leu	Gln	Phe	His	Leu	Leu	Arg	Arg	Asn	Arg	Gln	Gly
70						180				185			190			
75	Asp	Val	Gly	Gly	Thr	Cys	Gly	Val	Val	Asp	Asp	Glu	Pro	Arg	Pro	Thr
						195				200			205			
	Gly	Lys	Ala	Glu	Thr	Glu	Asp	Glu	Asp	Glu	Gly	Thr	Glu	Gly	Glu	Asp
80						210			215			220				
85	Glu	Gly	Pro	Gln	Trp	Ser	Pro	Gln	Asp	Pro	Ala	Leu	Gln	Gly	Val	Gly
						225			230			235			240	
	Gln	Pro	Thr	Gly	Thr	Gly	Ser	Ile	Arg	Lys	Lys	Arg	Phe	Val	Ser	Ser
90						245			250			255				
95	His	Arg	Tyr	Val	Glu	Thr	Met	Leu	Val	Ala	Asp	Gln	Ser	Met	Ala	Glu

## EP 0874 050 A2

	260.	265	270
	Phe His Gly Ser Gly Leu Lys His Tyr Leu Leu Thr Leu Phe Ser Val		
5	275	280	285
	Ala Ala Arg Leu Tyr Lys His Pro Ser Ile Arg Asn Ser Val Ser Leu		
	290	295	300
	Val Val Val Lys Ile Leu Val Ile His Asp Glu Gln Lys Gly Pro Glu		
10	305	310	315
	320		
	Val Thr Ser Asn Ala Ala Leu Thr Leu Arg Asn Phe Cys Asn Trp Gin		
	325	330	335
	Lys Gln His Asn Pro Pro Ser Asp Arg Asp Ala Glu His Tyr Asp Thr		
15	340	345	350
	Ala Ile Leu Phe Thr Arg Gln Asp Leu Cys Gly Ser Gln Thr Cys Asp		
	355	360	365
	Thr Leu Gly Met Ala Asp Val Gly Thr Val Cys Asp Pro Ser Arg Ser		
20	370	375	380
	Cys Ser Val Ile Glu Asp Asp Gly Leu Gln Ala Ala Phe Thr Thr Ala		
	385	390	395
	400		
	His Glu Leu Gly His Val Phe Asn Met Pro His Asp Asp Ala Lys Gln		
25	405	410	415
	Cys Ala Ser Leu Asn Gly Val Asn Gln Asp Ser His Met Met Ala Ser		
	420	425	430
	Met Leu Ser Asn Leu Asp His Ser Gln Pro Trp Ser Pro Cys Ser Ala		
30	435	440	445
	Tyr Met Ile Thr Ser Phe Leu Asp Asn Gly His Gly Glu Cys Leu Met		
	450	455	460
	Asp Lys Pro Gln Asn Pro Ile Gln Leu Pro Gly Asp Leu Pro Gly Thr		
35	465	470	475
	480		
	Ser Tyr Asp Ala Asn Arg Gln Cys Gln Phe Thr Phe Gly Glu Asp Ser		
	485	490	495
	500		
	Lys His Cys Pro Asp Ala Ala Ser Thr Cys Ser Thr Leu Trp Cys Thr		
40	505	510	
	Gly Thr Ser Gly Gly Val Leu Val Cys Gln Thr Lys His Phe Pro Trp		
	515	520	525
	530		
	Ala Asp Gly Thr Ser Cys Gly Glu Gly Lys Trp Cys Ile Asn Gly Lys		
45	535	540	
	Cys Val Asn Lys Thr Asp Arg Lys His Phe Asp Thr Pro Phe His Gly		
	545	550	555
	560		
	Ser Trp Gly Met Trp Gly Pro Trp Gly Asp Cys Ser Arg Thr Cys Gly		
50	565	570	575
	580		
	Gly Gly Val Gin Tyr Thr Met Arg Glu Cys Asp Asn Pro Val Pro Lys		
	585	590	
	595		
	Asn Gly Gly Lys Tyr Cys Glu Gly Lys Arg Val Arg Tyr Arg Ser Cys		
55	600	605	

**EP 0 874 050 A2**

	Asn Leu Glu Asp Cys Pro Asp Asn Asn Gly Lys Thr Phe Arg Glu Glu			
	610	615	620	
5	Gln Cys Glu Ala His Asn Glu Phe Ser Lys Ala Ser Phe Gly Ser Gly			
	625	630	635	640
	Pro Ala Val Glu Trp Ile Pro Lys Tyr Ala Gly Val Ser Pro Lys Asp			
	645	650	655	
10	Arg Cys Lys Leu Ile Cys Gln Ala Lys Gly Ile Gly Tyr Phe Phe Val			
	660	665	670	
	Leu Gln Pro Lys Val Val Asp Gly Thr Pro Cys Ser Pro Asp Ser Thr			
	675	680	685	
15	Ser Val Cys Val Gln Gly Gln Cys Val Lys Ala Gly Cys Asp Arg Ile			
	690	695	700	
	Ile Asp Ser Lys Lys Phe Asp Lys Cys Gly Val Cys Gly Gly Asn			
	705	710	715	720
20	Gly Ser Thr Cys Lys Lys Ile Ser Gly Ser Val Thr Ser Ala Lys Pro			
	725	730	735	
	Gly Tyr His Asp Ile Ile Thr Ile Pro Thr Gly Ala Thr Asn Ile Glu			
	740	745	750	
25	Val Lys Gln Arg Asn Gln Arg Gly Ser Arg Asn Asn Gly Ser Phe Leu			
	755	760	765	
	Ala Ile Lys Ala Ala Asp Gly Thr Tyr Ile Leu Asn Gly Asp Tyr Thr			
	770	775	780	
30	Leu Ser Thr Leu Glu Gln Asp Ile Met Tyr Lys Gly Val Val Leu Arg			
	785	790	795	800
	Tyr Ser Gly Ser Ser Ala Ala Leu Glu Arg Ile Arg Ser Phe Ser Pro			
	805	810	815	
35	Leu Lys Glu Pro Leu Thr Ile Gln Val Leu Thr Val Gly Asn Ala Leu			
	820	825	830	
	Arg Pro Lys Ile Lys Tyr Thr Val Phe Val Lys Lys Lys Glu Ser			
	835	840	845	
40	Phe Asn Ala Ile Pro Thr Phe Ser Ala Trp Val Ile Glu Glu Trp Gly			
	850	855	860	
	Glu Cys Ser Lys Ser Cys Glu Leu Gly Trp Gln Arg Arg Leu Val Glu			
	865	870	875	880
45	Cys Arg Asp Ile Asn Gly Gln Pro Ala Ser Glu Cys Ala Lys Glu Val			
	885	890	895	
	Lys Pro Ala Ser Thr Arg Pro Cys Ala Asp His Pro Cys Pro Gln Trp			
	900	905	910	
50	Gln Leu Gly Glu Trp Ser Ser Cys Ser Lys Thr Cys Gly Lys Gly Tyr			
	915	920	925	
	Lys Lys Arg Ser Leu Lys Cys Leu Ser His Asp Gly Gly Val Leu Ser			
	930	935	940	
55	His Glu Ser Cys Asp Pro Leu Lys Lys Pro Lys His Phe Ile Asp Phe			

945                    950                    955                    960  
 Cys Thr Met Ala Glu Cys Ser  
 5                                                965

## 10                    (2) INFORMATION FOR SEQ ID NO: 3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

20                    (ii) MOLECULE TYPE: cDNA  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

25                    ACTGTGTGTG ATCCGAG

17

## (2) INFORMATION FOR SEQ ID NO: 4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

40                    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

45                    GTTGGAAAGC ATTGACG

17

**Claims**

1. An isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the ITGL-TSP polypeptide of SEQ ID NO:2 over its entire length; or a nucleotide sequence complementary to said nucleotide sequence.
2. The polynucleotide of claim 1 which is DNA or RNA.
3. The polynucleotide of claim 1 wherein said nucleotide sequence is at least 80% identical to that contained in SEQ ID NO:1.
4. The polynucleotide of claim 3 wherein said nucleotide sequence comprises the ITGL-TSP polypeptide encoding

sequence contained in SEQ ID NO:1.

5. The polynucleotide of claim 3 which is polynucleotide of SEQ ID NO: 1.
6. A DNA or RNA molecule comprising an expression system, wherein said expression system is capable of producing a ITGL-TSP polypeptide comprising an amino acid sequence, which has at least 80% identity with the polypeptide of SEQ ID NO:2 when said expression system is present in a compatible host cell.
7. A host cell comprising the expression system of claim 6.
- 10 8. A process for producing a ITGL-TSP polypeptide comprising culturing a host of claim 7 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.
9. A process for producing a cell which produces a ITGL-TSP polypeptide thereof comprising transforming or trans-15 fecting a host cell with the expression system of claim 6 such that the host cell, under appropriate culture conditions, produces a ITGL-TSP polypeptide.
10. A ITGL-TSP polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO:2 over its entire length.
- 20 11. The polypeptide of claim 10 which comprises the amino acid sequence of SEQ ID NO:2.
12. An antibody immunospecific for the ITGL-TSP polypeptide of claim 10.
- 25 13. A method for the treatment of a subject in need of enhanced activity or expression of ITGL-TSP polypeptide of claim 10 comprising:
  - (a) administering to the subject a therapeutically effective amount of an agonist to said polypeptide; and/or
  - (b) providing to the subject a polynucleotide of claim 1 in a form so as to effect production of said polypeptide 30 activity *in vivo*.
14. A method for the treatment of a subject having need to inhibit activity or expression of ITGL-TSP polypeptide of claim 10 comprising:
  - (a) administering to the subject a therapeutically effective amount of an antagonist to said polypeptide; and/or
  - (b) administering to the subject a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding said polypeptide; and/or
  - (c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said polypeptide for its ligand, substrate, or receptor.
- 35 40 15. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of ITGL-TSP polypeptide of claim 10 in a subject comprising:
  - (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said ITGL-TSP polypeptide in the genome of said subject; and/or
  - (b) analyzing for the presence or amount of the ITGL-TSP polypeptide expression in a sample derived from said subject.
- 45 50 16. A method for identifying compounds which inhibit (antagonize) or agonize the ITGL-TSP polypeptide of claim 10 which comprises:
  - (a) contacting a candidate compound with cells which express the ITGL-TSP polypeptide (or cell membrane expressing ITGL-TSP polypeptide) or respond to ITGL-TSP polypeptide; and
  - (b) observing the binding, or stimulation or inhibition of a functional response; or comparing the ability of the cells (or cell membrane) which were contacted with the candidate compounds with the same cells which were not contacted for ITGL-TSP polypeptide activity.
- 55 17. An agonist identified by the method of claim 16.

**18. An antagonist identified by the method of claim 16.**

**5**

**10**

**15**

**20**

**25**

**30**

**35**

**40**

**45**

**50**

**55**